PALLAS研究:哌柏西利联合辅助内分泌治疗早期乳腺癌的期中分析
PALLAS是一项多中心、开放标签、随机3期研究,纳入5760例II-III期激素受体阳性/HER2阴性早期乳腺癌患者,比较2年哌柏西利联合辅助内分泌治疗与单纯内分泌治疗。
要点
- 2年辅助哌柏西利联合内分泌治疗未改善侵袭性疾病生存。
核心结论
- 在第二次预设期中分析中,辅助内分泌治疗联合2年哌柏西利较单纯内分泌治疗未改善侵袭性疾病生存。
- 基于此结果,该方案不推荐用于辅助治疗场景。
研究设计与样本
- PALLAS为正在进行的多中心、开放标签、随机3期研究,纳入21个国家406个中心的II-III期激素受体阳性/HER2阴性乳腺癌患者。
- 共5760例患者按1:1随机分配至哌柏西利(125 mg口服,每日一次,每28天周期第1-21天,共2年)联合内分泌治疗组(n=2883)或单纯内分泌治疗组(n=2877)。
- 主要终点为意向治疗人群的无侵袭性疾病生存,本次为第二次预设期中分析,触发时已观察到预期侵袭性疾病生存事件总数的67%。
主要发现
- 因检验统计量跨过预设无效边界,独立数据监测委员会建议停止仍在接受哌柏西利联合内分泌治疗患者的哌柏西利。
关键数值与推荐
- 未发生治疗相关死亡。
临床怎么用
- 基于本次期中分析,不推荐在早期乳腺癌辅助治疗中联合使用2年哌柏西利。
- 对于仍在接受辅助哌柏西利联合内分泌治疗的患者,应考虑停用哌柏西利。
- 需关注哌柏西利联合内分泌治疗时中性粒细胞减少等血液学毒性及严重不良事件风险。
局限性
- 研究为开放标签设计,未设盲。
- 长期随访和转化研究仍在进行中。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Palbociclib added to endocrine therapy improves progression-free survival in hormone-receptor-positive, HER2-negative, metastatic breast cancer. The PALLAS trial aimed to investigate whether the addition of 2 years of palbociclib to adjuvant endocrine therapy improves invasive disease-free survival over endocrine therapy alone in patients with hormone-receptor-positive, HER2-negative, early-stage breast cancer. METHODS: PALLAS is an ongoing multicentre, open-label, randomised, phase 3 study that enrolled patients at 406 cancer centres in 21 countries worldwide with stage II-III histologically confirmed hormone-receptor-positive, HER2-negative breast cancer, within 12 months of initial diagnosis. Eligible patients were aged 18 years or older with an Eastern Cooperative Oncology Group performance score of 0 or 1. Patients were randomly assigned (1:1) in permuted blocks of random size (4 or 6), stratified by anatomic stage, previous chemotherapy, age, and geographical region, by use of central telephone-based and web-based interactive response technology, to receive either 2 years of palbociclib (125 mg orally once daily on days 1-21 of a 28-day cycle) with ongoing standard provider or patient-choice adjuvant endocrine therapy (tamoxifen or aromatase inhibitor, with or without concurrent luteinising hormone-releasing hormone agonist), or endocrine therapy alone, without masking. The primary endpoint of the study was invasive disease-free survival in the intention-to-treat population. Safety was assessed in all randomly assigned patients who started palbociclib or endocrine therapy. This report presents results from the second pre-planned interim analysis triggered on Jan 9, 2020, when 67% of the total number of expected invasive disease-free survival events had been observed. The trial is registered with ClinicalTrials.gov (NCT02513394) and EudraCT (2014-005181-30). FINDINGS: Between Sept 1, 2015, and Nov 30, 2018, 5760 patients were randomly assigned to receive palbociclib plus endocrine therapy (n=2883) or endocrine therapy alone (n=2877). At the time of the planned second interim analysis, at a median follow-up of 23·7 months (IQR 16·9-29·2), 170 of 2883 patients assigned to palbociclib plus endocrine therapy and 181 of 2877 assigned to endocrine therapy alone had invasive disease-free survival events. 3-year invasive disease-free survival was 88·2% (95% CI 85·2-90·6) for palbociclib plus endocrine therapy and 88·5% (85·8-90·7) for endocrine therapy alone (hazard ratio 0·93 [95% CI 0·76-1·15]; log-rank p=0·51). As the test statistic comparing invasive disease-free survival between groups crossed the prespecified futility boundary, the independent data monitoring committee recommended discontinuation of palbociclib in patients still receiving palbociclib and endocrine therapy. The most common grade 3-4 adverse events were neutropenia (1742 [61·3%] of 2840 patients on palbociclib and endocrine therapy vs 11 [0·3%] of 2903 on endocrine therapy alone), leucopenia (857 [30·2%] vs three [0·1%]), and fatigue (60 [2·1%] vs ten [0·3%]). Serious adverse events occurred in 351 (12·4%) of 2840 patients on palbociclib plus endocrine therapy versus 220 (7·6%) of 2903 patients on endocrine therapy alone. There were no treatment-related deaths. INTERPRETATION: At the planned second interim analysis, addition of 2 years of adjuvant palbociclib to adjuvant endocrine therapy did not improve invasive disease-free survival compared with adjuvant endocrine therapy alone. On the basis of these findings, this regimen cannot be recommended in the adjuvant setting. Long-term follow-up of the PALLAS population and correlative studies are ongoing. FUNDING: Pfizer.
引用
- Mayer EL, Dueck AC, Martin M, et al. Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2021. PMID: 33460574. doi:10.1016/S1470-2045(20)30642-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。